Page last updated: 2024-12-05
talactoferrin alfa
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5619 |
| CHEMBL ID | 290543 |
| CHEBI ID | 103981 |
| SCHEMBL ID | 332192 |
| MeSH ID | M0504489 |
Synonyms (15)
| Synonym |
|---|
| BRD-A12822115-003-01-6 |
| L000607 |
| CHEBI:103981 |
| talactoferrin alfa |
| bdbm86547 |
| cas_135349 |
| nsc_135349 |
| SCHEMBL332192 |
| 2-(3,4-dichlorophenyl)-n-methyl-n-[2-(1-pyrrolidinyl)cyclohexyl]acetamide |
| Q27181219 |
| 3,4-dichloro-n-methyl-n-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide |
| CHEMBL290543 |
| 149341-39-9 |
| 3,4-dichloro-n-methyl-n-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide |
| DTXSID101155047 |
Research Excerpts
Overview
Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI) It is a recombinant form of the human glycoprotein, lactoferr in. It has been shown to have a wide range of effects on the immune system.
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "TLF, in combination with C/P, demonstrated an apparent improvement in RR, PFS, and OS in patients with previously untreated stage IIIB/IV non-small cell lung cancer and appears to enhance activity without significant additional toxicity." | ( A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. Advani, SH; Bapna, A; Digumarti, R; Doval, DC; Julka, PK; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Raman, G; Ranade, AA; Varadhachary, A; Wang, Y, 2011) | 0.37 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.62) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (43.48%) | 5.53% |
| Reviews | 3 (13.04%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (43.48%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (7)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis [NCT00630656] | Phase 2 | 190 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC) [NCT00923741] | Phase 1 | 10 participants (Actual) | Interventional | 2008-06-19 | Completed | ||
| Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants [NCT00854633] | Phase 1/Phase 2 | 120 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer [NCT00706862] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2009-02-28 | Recruiting | ||
| A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) [NCT01528137] | Phase 1 | 4 participants (Actual) | Interventional | 2012-05-31 | Terminated(stopped due to Negative data from another trial led to termination of this trial by sponsor.) | ||
| FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens [NCT00707304] | Phase 3 | 742 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis [NCT01273779] | Phase 2/Phase 3 | 1,280 participants (Anticipated) | Interventional | 2011-06-30 | Suspended(stopped due to Data Safety Monitoring Board recommendation) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||